| | | | | | . 10 . 20 . 30 . 40 . 50 . 60 . 70 . 80 . 90 . 100 . 110 . 120 . 130 . 140 . 150 . 160 . 170 . 180 . 190 . 200 . 210 . 220 . 230 . 240 . 250 . 260 . 270 . 280 . 290 . 300 . 310 . 320 . 330 . |
# |
Score |
Template |
Links and tools | %id | First |
GSHSMRYFYTAMSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIFKTNTQTYRENLRIALRYYNQSEAGSHTWQTMYGCDLGPDGRLLRGHNQLAYDGKDYIALNEDLSSWTAADTAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQRADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTIPIVGIVAGLAVLAVVVIGAVVATVMCRRKSSGGKGGSYSQAASSDSAQGSDVSLTA | Last |
1 | -62.800 | PF00129.18; HA10_MOUSE/25-203; Class I Histocompatibility antigen, domains alpha 1 and 2 |
ali follow.. |
73 | 1 | GSHSMRYFETSVSRPGLGEPRFIIVGYVDDTQFVRFDSDAETPRMEPRAPWMEQEGPEYWERETQRAKGNEQSFHVSLRTLLGYYNQSESGSHTIQWMYGCKVGSDGRFLRGYLQYAYDGRDYIALNEDLKTWTAADVAAIITRRKWEQAGAAEYYRAYLEAECVEWLLRYLELGKETL............................................................................................................................................................... |
179 |
2 | -49.200 | PF14586.6; RAE1C_MOUSE/31-204; Class I Histocompatibility antigen, NKG2D ligand, domains 1 and 2 |
ali follow.. |
16 | 2 | .AHSLRCNLTIKAPTPADPLWYEAKCLVDEILILHLSNINKTMTSGD--PGETANATEVGECLTQPVNDLCQKLRDKVSNTKVDTHKTNGYPHLQVTM--IYPQSQGQTPSATWEFNISDSYFFTFYTENMSWRSANDESGVIMNKWNDDGDLVQRLKYFIPECRQKIDEFLKQSKEK................................................................................................................................................................ |
174 |
3 | -40.200 | PF16497.5; G1L1W7_AILME/2-199; MHC-I family domain |
ali follow.. |
14 | 24 | EPISLRIILTSSF-YNRSRTQNLASAWLDELQTHGWDSKTGAFIFLWP-WSRGNLSNEEVIRAEEAFYSNSIGLPLCFHDHFSEWQLEYP---FQVQLTGGCELHFGEPSVGFIRIAYEGSDLVSFQNMSWWPSEGGSRAQQVCRLFNQDHEDNELMHKLITDHCPRYLSSLLDAGKA................................................................................................................................................................ |
197 |
4 | -36.100 | PF07654.15; H9GZQ9_HORSE/236-322; Immunoglobulin C1-set domain |
ali follow.. |
23 | 7 | .............................................................................................................................................................................................HPDELSKSKVSVTCLVKDFYPPEINIEWQSNGQPELETYSTTQAQQDSDGSYFLYSKLSVDRNRGTTFTCGVMHEAL........................................................................ |
87 |
5 | -33.600 | PF15028.6; A0A2I3G3P5_NOMLE/20-146; Pre-T-cell antigen receptor |
ali follow.. |
15 | 2 | ....................................................................................................................................................................................VGGTLFPSLMLLVDGKQQMVVVCLVLDVAPPGFNPIWFSAGNGSALDAFTYGPSPATDGTWTNLAHLSLPSEEWEPLVCHTRPGAEGHSRSTQPLQLSGEASTARTC................................................... |
116 |
6 | -24.200 | PF05790.15; Q9GKR2_BOVIN/422-510; Immunoglobulin C2-set domain |
ali follow.. |
13 | 1 | ......................................................................................................................................................................................................VTVSCRVPNVYPDQLEIELFKGESIMMNKTFSKD--VSKKALETKSLEKTFIPTTEDVLVCLARLPIDEMEFELKQRQSTQTLY........................................................ |
86 |
7 | -22.400 | PF08205.12; BCAM_BOVIN/150-248; CD80-like C2-set immunoglobulin domain |
ali follow.. |
12 | 1 | ........................................................................................................................................................................................PEVSPNKGMDDFAQEIATCSSRNGNPAP-QIMWYRNGQPLAEGYMTTRTVREASGLLSLTSTLYLRLHKPDRFHCSVHYYLPAGQ..................................................................... |
98 |
8 | -22.300 | PF00047.25; OX2G_MOUSE/143-229; Immunoglobulin domain |
ali follow.. |
16 | 1 | .........................................................................................................................................................................................PIVHLHYNYFEDHLNITCSATA-RPAP-AISWKGTGTGIENST---ESHFHSNGTTSVTSILRVKDQVGKEVICQVLYLGNVIDYKQSL................................................................ |
87 |
9 | -21.300 | PF09085.10; H0WQ95_OTOGA/112-222; Adhesion molecule, immunoglobulin-like |
ali follow.. |
10 | 3 | ......................................................................................................................................................................................PDQLTVSPATLVPGVDQEVACTAHKVTPDALSFSLILGDRELEGPEIEEEPQEDEDLLFHVTQRWLLPPPILPNLYCQATMRLPGLELSRH................................................................. |
105 |
10 | -16.700 | PF08204.11; Q9Q8V0_RFVKA/10-120; CD47 immunoglobulin-like domain |
ali follow.. |
15 | 18 | .........................................................................................................................................................................................KVTVMPYTVCNTTITLECNLDELIYNSIHVKWLFYTMDDT----------ISNITNGSFIKFDFAKNLSGNYTCEAYSDLNSVKNVIALN............................................................... |
100 |
11 | -16.200 | PF05566.12; IL18B_VACCW/1-126; Orthopoxvirus interleukin 18 binding protein |
ali follow.. |
14 | 20 | .......................................................................................................................................................................................ADEIKCPNLNIVTSSGEFRCTGCKFMPNFSYMYWLAKDMRSDEDAKFIEHLGEGGRIVTLQKVLDTNKFDNYRFTCVLTTIDGVSKKNIWLK............................................................... |
126 |
12 | -14.300 | PF13927.6; H9IS41_BOMMO/56-136; Immunoglobulin domain |
ali follow.. |
18 | 1 | .......................................................................................................................................................................................PPIVRVEPKNIEGSKLLLKCEYESNPSSLSAVFWFRDGERVNVNDTAH--YQGGTTDQHSLIIMNARGVDMGNYTCLLTN........................................................................... |
81 |
13 | -13.000 | PF13895.6; F6QPE0_BOVIN/327-404; Immunoglobulin domain |
ali follow.. |
18 | 1 | .......................................................................................................................................................................................KPKLESSATHLDQGELNLWCSIPG-APP-ANFTIQKGSMTVSQTQN---------------FTKRVSEWDSGLYTCVAGVFKRSNTVQIT................................................................. |
77 |
14 | -13.000 | PF17736.1; A0A096NT62_PAPAN/27-121; C17orf99 Ig domain |
ali follow.. |
10 | 1 | ........................................................................................................................................................................................PVVSIAYKVPKGRRVLITCHAPQASPPITYSLCGTKNIEVAKKVVKTHEPASFNLNIT-----LKSSPDLLTYFCRAATTVDSARLQMYWE............................................................... |
94 |
15 | -11.400 | PF07686.17; A2BGB5_DANRE/30-142; Immunoglobulin V-set domain |
ali follow.. |
16 | 6 | ...............................................................................................................................................................................................EAVNGTEIRLKCTFKSNRPERTSVSWSFPGGLFKDHVVWSGDVMKGDGSITLQ---DVQFSFNGTYSCQVLNPP......................................................................... |
100 |
16 | -11.200 | PF16681.5; F1SAK8_PIG/36-116; Ig-like domain on T-cell surface glycoprotein CD3 epsilon chain |
ali follow.. |
17 | 6 | ..................................................................................................................................................................................................SGDKVELTCPEDP---ESEKMTWKRNDMQIYESYDNYMLLES-----------FSEVENSGYYTCTVGEK.......................................................................... |
61 |
17 | -10.500 | PF07679.16; Q9GV22_MYTGA/647-736; Immunoglobulin I-set domain |
ali follow.. |
13 | 11 | ...............................................................................................................................................................................................SLNEGDRLKLTCTVKG-QPEP-EVEWFYNGQLMQSD---DAIKISAIAGHHTLTIDSCIIDDDGNYVCKAKNP.......................................................................... |
78 |
18 | -10.100 | PF16706.5; IZUM1_RAT/168-255; Izumo-like Immunoglobulin domain |
ali follow.. |
7 | 4 | ...............................................................................................................................................................................................EVHRLEDMVLDCQLSW--HHASEGLTDYSFYRVWGNSSETLMSKGKEPYLTKT---MVGPEDAGNYRCELDTVNAGPATIIYYH............................................................... |
82 |
19 | -10.100 | PF02440.15; Q6QPD0_9ADEN/15-113; Adenovirus E3 region protein CR1 |
ali follow.. |
15 | 1 | .........................................................................................................................................................................................ALCESVDRDVTITTGSNYTLKG-PPSG-MLSWYCYFGTDTDQTELCNNYQCNGTDLIL---LNVTKAYGGSYYCPGQNT.......................................................................... |
86 |
20 | -9.640 | PF00969.19; Q3UUV9_MOUSE/43-114; Class II histocompatibility antigen, beta domain |
ali follow.. |
9 | 2 | ....................................................................................................CHYFNGKERVWSVTRFIYNQEEFARFNSDFGKFLAVTELGRPIVEYLNTQKDMLDNYRASVDRC.............................................................................................................................................................................. |
65 |
21 | -9.620 | PF15910.5; A0A287A7M9_PIG/23-135; ICOS V-set domain |
ali follow.. |
9 | 9 | ...............................................................................................................................................................................................FMFHDGGLQIVCKYPD---RQFKMQLLKGKNILTNVNLCQFQLSNNSVSFFLY---NLDSSYASYYICELS............................................................................ |
90 |
22 | -9.470 | PF06623.11; F7C2F9_HORSE/248-275; MHC_I C-terminus |
ali follow.. |
73 | 1 | ........................................................................................................................................................................................................................................................................................................................SGREGRSYTQAAGSDSAQGSDVSLMD |
26 |